Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159063 | 1.00 | CTSB (0.41) | CTSBPPP3CB | |
| SCHEMBL13051897 | 1.00 | CTSB (0.41) | CTSBPPP3CB | |
| SCHEMBL14588795 | 0.94 | — | — | |
| SCHEMBL8281563 | 0.94 | CTSB (0.43) | CTSBPPP3CB | |
| SCHEMBL13981170 | 0.93 | — | — | |
| SCHEMBL6877935 | 0.91 | CYP3A4 (0.43) | CTSBPPP3CB | |
| SCHEMBL10060996 | 0.91 | CYP3A4 (0.43) | CTSBPPP3CB | |
| SCHEMBL10052378 | 0.91 | CYP3A4 (0.43) | CTSBPPP3CB | |
| SCHEMBL16508713 | 0.91 | CYP3A4 (0.43) | CTSBPPP3CB | |
| SCHEMBL12809028 | 0.89 | CTSB (0.35) | CTSBPPP3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687021-B1 | METHOD OF REMOVING TRANSITION METALS, ESPECIALLY FROM METATHESIS REACTION PRODUCTS | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-7749961-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7749961-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-1699558-B1 | REMOVAL OF RUTHENIUM BY-PRODUCT BY SUPERCRITICAL FLUID PROCESSING | BOEHRINGER INGELHEIM INT (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-7449591-B2 | Process of removing transition metals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-11 | — | — | US | disclosed |
| US-7268211-B2 | Removal of ruthenium by-product by supercritical fluid processing | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-11 | — | — | US | disclosed |
| US-7268211-B2 | Removal of ruthenium by-product by supercritical fluid processing | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-11 | — | — | US | disclosed |
| US-7241898-B2 | Metathesis catalysts | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241898-B2 | Metathesis catalysts | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7189844-B2 | Ring-closing metathesis process in supercritical fluid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7189844-B2 | Ring-closing metathesis process in supercritical fluid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7183374-B2 | Method of removing transition metals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-7183374-B2 | Method of removing transition metals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RPP30, RNASE1 | CTSB 177/4885PPP3CB 1178/4885 |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RNPEP, RNASE1 | CTSB 98/4885PPP3CB 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.